Healthpoint buy to double Smith & Nephew’s US wound operations

Date November 28, 2012

Smith & Nephew has long been spoken of as a takeover target, but instead it has itself pounced on Healthpoint Biotherapeutics, a specialist in bioactive woundcare – the fastest-growing area in the wound management sector. The $782m acquisition, financed with a combination of existing cash and debt, allows S&N access to the $1bn biotherapeutics market. It ought to close this year; S&N must pay an additional $10m if completion comes after December 31.

The privately held Healthpoint looks like a sensible purchase, with 2011 revenue of $151m and profit of $11m, as well as double-digit growth. The deal will double the size of S&N’s US wound management operations, signalling a desire to build on its traditional bastion in Europe, where its woundcare business is the market leader. Nonetheless, the UK company’s shares fell 1.4% to 649.5p on the London stock exchange.

Paid full price

Healthpoint’s biggest driver is Santyl, an ointment containing collagenase used to debride dermal ulcers and burns, in which, oddly enough, S&N formerly had an interest - rights to 75% of Santyl revenue in a deal struck with its then-manufacturer, Abbott Laboratories. S&N exited the deal in 2003 owing to manufacturing issues, “long since resolved in Healthpoint’s hands”.

Healthpoint's other products include Oasis, a family of leading acellular skin substitutes for venous leg ulcers and diabetic foot ulcers, and Regranex, a topical gel containing a growth factor for neuropathic foot ulcers in diabetics. S&N said the product portfolio should deliver growth at “a mid-teen percentage rate for the next few years”.

Healthpoint is expected to generate revenues of $190m in 2012, so at more than four times sales S&N has paid a relatively high multiple, although this would be mitigated if the expected growth materialses.


Eventually, and gradually, Healthpoint will be integrated into S&N’s advanced wound management division. The company expects $20m in efficiency savings by 2015, but will spend $25m on aligning the two businesses. Healthpoint’s 460 employees, including a 215-strong sales force, will continue to be headquartered in Fort Worth, Texas.

Healthpoint’s lead product candidate, called HP802-247, is a cell-based therapy containing keratinocytes and fibroblasts and has started phase III trials for the treatment of venous leg ulcers. Launch is pencilled in for 2017.

Smith & Nephew will have to make a significant R&D investment in HP802-247, funding phase III and commercialisation over the next five years; it says it will spend $40-50m a year on Healthpoint’s R&D, an increase from $23m in 2011.


Bernstein analysts said that S&N’s investors would have to decide whether the company should be spending money on M&A or returning cash to shareholders. They noted that bioactive products lying somewhere between pharma and medtech, and a phase III candidate, are riskier elements than S&N’s shareholders might be used to.

At $782m, the deal is one of the top 10 M&As done this year so far – even if Baxter’s much hinted-at purchase of Gambro comes off in the next few weeks (2012 sees largest pure medtech buy for seven years, but value of deals slump 27%, October 29, 2012). Owing to the debt financing element and Healthpoint's marginal profitability the acquisition will be neutral to S&N's earnings in 2013 and accretive in 2014 – though only very slightly according to UBS analysts – with profitability accelerating thereafter.

According to EvaluateMedtech, the wound management sector was worth $12bn last year and, with an annual growth rate of 5%, is expected to reach $16bn in 2018. Smith & Nephew clearly believes that buying Healthpoint will enable it to outpace the market. 

To contact the writer of this story email Elizabeth Cairns in London at elizabethc@epvantage.com

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd